{"title":"The 3PM transformation potential of minimal residual disease in solid tumor management: a bibliometric analysis and review.","authors":"Yining Chen, Xin Li, Suya Zhao, Yuchong Zhang, Haixu Wang, Fangjian Na, Qi Guan, Zhi Li, Heming Li, Mingfang Zhao","doi":"10.1007/s13167-025-00413-8","DOIUrl":null,"url":null,"abstract":"<p><p>Over the past two decades, significant progress has been made in the study of minimal residual disease (MRD) in patients with solid tumors. Increasing evidence supports that monitoring and quantifying MRD can provide prognostic insights and enable personalized treatment strategies for patients who achieve complete remission. Although MRD is gradually being integrated into the clinical management of solid tumors, several challenges remain unresolved. This review combines bibliometric analysis with advances in cutting-edge technologies to examine the evolving landscape of MRD, emphasizing its alignment with the predictive, preventive, and personalized medicine (PPPM/3PM) paradigm. By synthesizing research trends, key challenges, and innovative approaches, we highlight the predictive value of MRD for relapse risk, its preventive role in early intervention, and its potential to guide real-time personalized therapies. We advocate for the standardization and integration of MRD monitoring into routine clinical oncology practice, reinforced by expert recommendations grounded in 3PM principles.</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s13167-025-00413-8.</p>","PeriodicalId":94358,"journal":{"name":"The EPMA journal","volume":"16 3","pages":"669-688"},"PeriodicalIF":5.9000,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12423022/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The EPMA journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s13167-025-00413-8","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/9/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
Over the past two decades, significant progress has been made in the study of minimal residual disease (MRD) in patients with solid tumors. Increasing evidence supports that monitoring and quantifying MRD can provide prognostic insights and enable personalized treatment strategies for patients who achieve complete remission. Although MRD is gradually being integrated into the clinical management of solid tumors, several challenges remain unresolved. This review combines bibliometric analysis with advances in cutting-edge technologies to examine the evolving landscape of MRD, emphasizing its alignment with the predictive, preventive, and personalized medicine (PPPM/3PM) paradigm. By synthesizing research trends, key challenges, and innovative approaches, we highlight the predictive value of MRD for relapse risk, its preventive role in early intervention, and its potential to guide real-time personalized therapies. We advocate for the standardization and integration of MRD monitoring into routine clinical oncology practice, reinforced by expert recommendations grounded in 3PM principles.
Supplementary information: The online version contains supplementary material available at 10.1007/s13167-025-00413-8.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
